Lisdexamfetamine for Binge Eating Disorder in Adults
Lisdexamfetamine for Binge Eating Disorder in Adults
LDX is the first pharmacological agent that has received regulatory approval for the treatment of BED. In three 11–12 week randomised placebo-controlled clinical trials, LDX 50 or 70 mg/day significantly reduced BED symptoms as measured by the number of binge eating days per week. Effect sizes were highly robust. Discontinuation rates because of AEs were low. Pending clinical trials include a long-term study examining maintenance of efficacy.
Conclusions
LDX is the first pharmacological agent that has received regulatory approval for the treatment of BED. In three 11–12 week randomised placebo-controlled clinical trials, LDX 50 or 70 mg/day significantly reduced BED symptoms as measured by the number of binge eating days per week. Effect sizes were highly robust. Discontinuation rates because of AEs were low. Pending clinical trials include a long-term study examining maintenance of efficacy.
Source...